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Abstract: Sperm fertility ability may be modulated by different molecular systems, such as the
renin-angiotensin system (RAS). Although renin is one of its most relevant peptides, the presence and
role of the (pro)renin receptor (PRR) is completely unknown. We have proved for the first time the
existence of PRR and its transcript in human sperm by western blot and RT-PCR. Immunofluorescence
studies showed that this receptor is mainly located in the apical region over the acrosome and in the
postacrosomal region of the sperm head and along the sperm tail. In addition, this prospective cohort
study also proves that semen samples with higher percentages of PRR-positive spermatozoa are
associated with poor sperm motility, worse blastocyst development and no-viable blastocysts. Our
results provide insight into how PRR play a negative role in sperm physiology that it may condition
human embryo quality and development. An in-depth understanding of the role of PRR in sperm
fertility can help elucidate its role in male infertility, as well as establish biomarkers for the diagnosis
or selection of sperm to use during assisted reproductive techniques.
Keywords: prorenin receptor; human; semen analysis; reproductive techniques; assisted; embry-
onic development
1. Introduction
Currently, over 186 million people worldwide have infertility problems [1], and male
factor represents 30 to 50 % of clinical infertility cases [2]. Abnormal sperm parameters
including low sperm concentration and poor sperm motility contribute to fertility prob-
lems [3]. However, 20 to 30 % of men with normal parameters have fertility problems
since they are unable to achieve pregnancy [4], suggesting that molecular deficiencies
not described yet could cause male infertility [5]. Over the last few years, several studies
have suggested that sperm molecular features, such as RNA and proteins, are involved
in fertilization and embryo development [3,5–8]. A better comprehension of those sperm
molecular characteristics will allow us to develop functionally relevant diagnostic and
sperm selection strategies to maximize reproductive success [9].
Different communication systems such as opioids [10], tachykinins [11] or the renin-
angiotensin system (RAS) [12–14] seem to be especially relevant in the regulation of sperm
fertility. RAS is a communication system with endocrine characteristics, whose main role
is to maintain blood pressure and the homeostasis of electrolytes and fluids. In addition,
RAS components can also locally synthesize in multiple tissues and cells suggesting that
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this physiological system also exerts different actions at the local level [15]. Angiotensin II,
angiotensin converting enzyme (ACE) and renin are the best-known active components of
the RAS [15]. In this sense, although Ang II and renin are not synthesized in sperm [16],
elevated levels of these proteins have been described in seminal plasma, which modulate
different sperm functions. For its part, sperm ACE (tACE) is involved in motility, capacita-
tion and acrosome reaction, and has been proposed as an essential protein in the fusion
process of sperm and oocytes, as it interacts with oocyte zona pellucida (ZP). In fact, the
aberrant, reduced or absent expression of tACE underlies failed fertilization, while fertility
is rescued when the functional tACE gene is reintroduced. Likewise, it has also been asso-
ciated with embryonic quality and development [13,14,17]. Although these peptides have
traditionally been considered as the main bioactive molecules of the RAS, currently several
studies have found new components of RAS that can activate different signal transduction
pathways [15,18,19]. The (pro)renin receptor (PRR), also called ATP6AP2, is a recently
reported component of the RAS. This transmembrane protein that can be activated directly
by prorenin (the precursor of the renin protein) and by the renin itself [15,20]. One of the
peculiarities of this receptor is that it is a main component of one of the new axes of the
RAS recently described, the prorenin-renin-PRR axis [21]. It has been reported that the
activation of PRR induces the lysis of angiotensinogen and, therefore, the synthesis of
angiotensin I is important for several processes, such as: (1) the activation of H+-ATPase,
(2) the formation of the Wnt receptor complex, and/or (3) the regulation of cell homeostasis
and autophagy [15,20,21].
In male reproductive tissues, renin has been found in the epididymis, testes and
seminal plasma [22], with higher levels of prorenin and renin in the latter than in blood
plasma [23]. Furthermore, it has been suggested that there is an association between the
prorenin levels of the seminal fluid and the quality of the semen [24]. However, there is
no direct evidence of the presence of PRR in sperm cells. Therefore, the objective of this
study was to determine whether PRR is present in human sperm. Once this first objective
was verified, its association with basic sperm parameters, oocyte fertilization, embryonic
development and reproductive success after in vitro fertilization (IVF) techniques was
evaluated, in order to elucidate its potential value as a sperm biomarker for improve
assisted reproduction techniques (ART).
2. Results
2.1. Patients and Seminal Samples
The mean age of the 97 men whose semen samples were used in this study was
39.39 ± 0.45 years, ranging between 32 and 52 years. The seminal characteristics of the
fresh semen samples and after preparation for in vitro fertilization techniques are indicated
in Table 1.
Table 1. Seminal characteristics of fresh semen samples and after preparation for in vitro fertiliza-
tion techniques.
Seminal Parameters Fresh Samples Processed Samples
Volume (mL) 2.99 ± 0.15 0.76 ± 0.02
Sperm concentration (×106 spz/mL) 75.31 ± 4.05 14.86 ± 1.19
Total sperm count (×106 spz) 205.94 ± 13.45 11.99 ± 1.13
Progressive motility (%) 54.42 ± 1.75 94.67 ± 0.49
Non-motile spermatozoa (%) 37.87 ± 1.49 4.54 ± 0.49
Results are expressed as mean ± SEM. Spz: spermatozoa.
2.2. Expression and Localization of PRR in Human Sperm
To study the PRR gene expression, we analyzed the presence of the ATP6AP2 transcript
in human sperm cells by RT-PCR (Figure 1A). We detected the expected 151-bp fragment in
human sperm samples and in the human renal cell line, which served as a positive control,
thus confirming that ATP6AP2 mRNA was present in human spermatozoa. The absence of
Int. J. Mol. Sci. 2021, 22, 3215 3 of 14
amplicons in negative controls—omitting cDNA—confirms the absence of genomic DNA
in each sample (Figure 1A).
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as a positive control. The anti-PRR polyclonal antibody showed immunoreactivity at 56 
kDa in human sperm protein extracts. In the kidney tissue, however, we detected two 
bands of 50 kDa and 70 KDa. No immunoreactivity was observed when the primary an-
tibody was omitted before secondary antibody addition. Flow cytometry analyses con-
firmed the presence of PRR in human spermatozoa and the 68.99 ± 1.75% of cells were 
positive for PRR (Figure 1C). To assure that the fluorescence came only from spermato-
zoa, PRR signal was only measured in Hoechst-positive cells. The specificity of the pri-
mary antibody was confirmed using non-specific rabbit immunoglobulin fraction at the 
same concentration as the primary antibody. Secondary antibody specificity was evalu-
ated by omitting the primary antibody before secondary antibody addition (Figure 1C).  
Figure 1. Expression and localization of PRR in human sperm cells. (A) A representative of midori-green-stained gels
of the RT-PCR products for ATP6AP2 and ACTB in human sperm from a pool of five normozoospermic semen samples
(Spz) and kidney (Kd). Primers without cDNA were used as negative control. (B) A representative immmunoblot of
PRR in human sperm from a pool of five normozoospermic samples (Spz) and kidney (kd). (C) A representative plot of
PRR-positive sperm population analyzed by flow cytometry. Plots of blank control (purple) without both primary and
secondary antibodies, negative primary antibody control (ligh blue) as the same concentration as the primary a tibody
and with econdary antibody, negativ secondary antibody co trol (deep blue) with secondary antibody alone, and plot
of PRR-positive sperm population (green). Nucleuses were stained with Hoescht 33258, n = 2. (D) Immunofluorescence
analysis of the PRR in human sperm cells. (D1) PRR Positive sperm cells (green). (D2) Negative secondary antibody control
(red). (D3) Phase-contrast image of the human sperm cells. Nucleuses were stained with Hoescht 33258. Representative
photomicrographs are shown; n = 3. Scale bar: 1 µm.
Next, we described the presence of PRR protein by immunoblotting. Figure 1B shows
a re resentative western blot using human sperm cells and hu an kidney, used as a
positive control. The anti-PRR polyclonal antibody showed immunoreactivity at 56 kDa
in human sperm protein extracts. In the kidney tissue, howe er, e detected two bands
of 50 kDa and 70 KDa. No immunore c ivity was observed hen the primary antib dy
was omitted befor secondary antibody addition. Flow cytometry analyses confirmed the
presence of PRR in human spermatozoa and the 68.99 ± 1.75% of cel s were positive for
PRR (Figure 1C). To assure that the fluorescence came only from spermatozoa, PRR signal
was o ly measured in Hoechst-positive cells. The spec ficity of the primary n ibody was
confirmed using on-sp cific r bbit immunoglobulin fr ction at the same concentr tion
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as the primary antibody. Secondary antibody specificity was evaluated by omitting the
primary antibody before secondary antibody addition (Figure 1C).
Finally, we also described the location of PRR in human spermatozoa by immunoflu-
orescence approaches. Immunocytochemistry studies confirmed the presence of PRR in
human sperm cells (Figure 1D). We observed a strong immunoreactivity mainly at the api-
cal region over the acrosome and at the postacrosomal region of the sperm head. Moreover,
we also observed a weak immunoreactivity along the sperm tail (Figure 1D). Cumulatively,
70% of cells were positive for PPR, confirming the results obtained by flow cytometry. Pri-
mary antibody specificity was confirmed by flow cytometry analysis. Fluorescent staining
pattern was not evidenced after omitting the primary anti-PRR antibody before secondary
antibody addition (Figure 1D).
2.3. Correlation between PRR with Basic Sperm Parameters
We analyzed the relationship between PRR and basic seminal parameters (concentra-
tion and motility) defined by the WHO [25]. The percentage of PRR-positive spermatozoa
was negatively correlated with the semen concentration and total sperm count (Table 2).
Regarding sperm motility, we observed a significant positive correlation between the
percentage of PRR-positive cells and the percentage of NP spermatozoa.
Table 2. Correlations between PRR with human sperm fertility status.
Fresh Samples Processed Samples
Total sperm count Correlation coefficient 0.043 −0.257 *
p value 0.676 0.011
Concentration
Correlation coefficient −0.091 −0.259 *




Correlation coefficient 0.087 −0.081
p value 0.399 0.428
Non-progressive
motility (NP)
Correlation coefficient 0.035 0.274 **
p value 0.736 0.007
Immotility (IM) Correlation coefficient −0.089 −0.025
p value 0.384 0.811
Spearman rank correlation coefficients analyses among the percentage of PRR-positive spermatozoa in association with sperm samples
concentration and the different types of motility. * Significant difference between groups (p < 0.05), and ** high significant difference
between groups (p < 0.01).
2.4. Percentage of PRR-Positive Sperm Cells and Fertilization and Embryo Quality
The total number of donated oocytes was 1038 and the mean was 10.70 ± 0.32 oocytes
received per donor. The fertilization rate of all cycles was 72.74% (70.34 ± 1.88%). 755 em-
bryos were analyzed, with a mean of 7.80 ± 0.28 embryos per couple.
In this prospective cohort study, we aimed to investigate the association between
PRR-positive sperm cells and fertilization rate and intracitoplasmatic sperm injection (ICSI)
outcomes in the cohort of zygotes obtained per recipient, although, for inherent reasons to
the study, we cannot be sure whether the injected sperm was PRR positive or negative.
First, we did not find any statistically significant correlation between PRR-positive
sperm and fertilization rates. We next studied the relationship between late or early
embryos and the percentage of PRR-positive sperm cells (measured at surplus sperm
after IVF procedures). The mean characteristics of our embryo cohort were as follows
(mean ± SEM): number of blastomeres on day two, 3.60 ± 0.05; embryo fragmentation
on day two, 2.30 ± 0.15%; number of blastomeres on day three, 6.55 ± 0.08; and finally,
embryo fragmentation on day three, 2.88 ± 0.17%. Concerning early embryo quality, we
did not find any significant difference between the percentage of PRR-positive spermatozoa
and embryo quality grades (p > 0.05) or embryo quality parameters (Table 3) on days two
and three of development.
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Table 3. Correlations between PRR-positive sperm cells and fertilization rate and embryo quality.
Correlation Coefficient p Value
Fertilization Rate −0.130 0.204
Day 2 embryo
Embryo quality 0.061 0.558
Number of blastomeres 0.084 0.423
Embryo fragmentation 0.071 0.490
Embryo symmetry 0.050 0.627
Day 3 embryo
Embryo quality 0.010 0.920
Number of blastomeres 0.053 0.605
Embryo fragmentation 0.118 0.257
Embryo symmetry 0.050 0.627
Spearman rank correlation coefficients analyses among the percentage of PRR-positive spermatozoa in association
with fertilization rate, embryo quality, average number of cells, average embryo fragmentation, and average
embryo symmetry on days 2 and 3 per patient.
Considering that blastocysts have a higher implantation potential than early em-
bryos, we also analyzed the association between PRR and the developmental stage of em-
bryos in the later phase of in vitro development (Figure 2A,B). We observed that blocked
or degenerated blastocysts (BD) were related to semen samples with higher levels of
PRR-positive spermatozoa than early (BT), expanded (BE) and hatching/hatched (BHi)
blastocysts (Figure 2B).
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Figure 2. Graphic representation of the scoring and viability of the embryo on day 5 and day 6
and the association with the percentage of PRR-positive spermatozoa. Percentage of PRR-positive
spermatozoa in association with the degree of development of the embryos on days 5 (A) and day
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difference between groups (p < 0.05); ** high significant difference between groups (p < 0.01).
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To evaluate the relationship between PRR and blastocyst viability, we classified em-
bryos into two groups: (1) embryos at the blastocyst stage were considered viable (V); and
(2) arrested, degenerated, and blastocysts with lower development were considered non-
viable (NV) (Figure 2C,D). Approximately 84% of the analyzed blastocysts were classified
as viable. NV human blastocyst also came from sperm samples with higher percentages of
PRR-positive spermatozoa (p < 0.05) (Figure 2C).
2.5. Percentage of PRR-Positive Sperm Cells and Embryo Transfer, Clinical Pregnancy and
Live-Birth Outcomes
Finally, we aimed to determine the relationship between sperm PRR and reproductive
success. The mean characteristics of the ART outcomes were as follows (mean ± SEM):
the number of embryos transferred per patient was 1.47 ± 0.06, the implantation rate was
52.25 ± 4.72, the mean frozen embryos per patient was 2.65 ± 0.25, and the number of
viable embryos (transferred and cryopreserved) per patient was 4.15 ± 0.27.
For the evaluation of the association of PRR and reproductive success, we only used
the first embryo transfer. A total of 89 of 97 cycles ended in embryo transfer (91.75% of
those included in the study). Of all the transfers carried out, 63 resulted in biochemical
pregnancies (70.78%), and later, 55 clinical pregnancies (61.79%) were confirmed by ultra-
sound. Finally, 49 cycles ended in a live birth (55.06% of the cycles with embryo transfer).
However, when we analyzed the relationship between these reproductive outcomes with
the percentage of PRR-positive spermatozoa, we did not find any statistically significant
relationships (Table 4).
Table 4. Association of sperm PRR levels with reproductive outcomes.
Yes No p(UMW)
Embryo transfer 72.26 (n = 89) 69.71 (n = 8) 0.704
Biochemical pregnancy 71.93 (n = 63) 74.22 (n = 26) 0.427
Clinical pregnancy 71.46 (n = 55) 75.00 (n = 34) 0.303
Live-birth outcome 71.46 (n = 49) 74.22 (n = 40) 0.453
The table shows the median values of each group. p: bilateral signification of the non-parametric Mann–Whitney
U-test analyses.
3. Discussion
Sperm functions and subsequent embryonic development are complex processes that
require tight regulation. In this regard, several cell communication systems are involved
in the regulation of human sperm fertility capacity [10,11], including RAS [12–14]. One
of the best-known components of the RAS is renin, an enzyme present in high levels in
seminal plasma that seems to be involved in sperm density and motility [24]. In addition,
different studies have also proved the involvement of tACE in sperm motility, capacitation,
the acrosome reaction and sperm-oocyte fusion [14]. The present work has described for
the first time the presence of PRR in human spermatozoa at the gene and protein level
providing new evidence of the prorenin-renin/PRR axis in human spermatozoa.
RT-PCR assays revealed the presence of the ATP6AP2 in human spermatozoa. It
has been suggested that a limited pool of RNAs is selectively retained and protected
from degradation in mature sperm [26]. Those retained RNAs could play several roles
in subsequent fertilization steps or in adequate embryo formation [27,28]. Hence, the
presence of the PRR transcript can be important for mature sperm cells to be subsequently
translated into protein upon fertilization [29]. However, mechanisms involving mRNA
storage and silencing of the transcription, as well as the functionality of the mRNA in
mature spermatozoa, is still a controversial issue that remains poorly understood [30].
Furthermore, this study has demonstrated the presence of PRR at the protein level
in mature human spermatozoa. A unique band of 56 kDa of PRR protein was detected in
human spermatozoa. Although the predicted molecular weight of this transmembrane
protein is 45 kDa [15], several studies show a disparity in the size of the bands observed
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in different cell types ranging from 28 to 74 kDa [31–33], suggesting the presence of
different isoforms of this receptor [34]. In addition, it has been reported that human
sperm cells present different isoform proteins compared to other cell types [35]. Indirect
immunofluorescence and flow cytometry analyses also confirm the presence of PRR on 70%
of human spermatozoa. Specifically, immunoreactivity was detected at the apical region
over the acrosome, at the postacrosomal region of the sperm head, and along the sperm
tail. Given these data, PRR could be involved in the regulation of essential functions in
sperm, such as motility, chemotaxis, sperm capacitation and/or acrosome reaction [35].
Basic semen analysis is the only routine clinical method to study male fertility status.
This morpho-functional analysis, however, is unable to predict the fertility potential and
reproductive outcome [4]. Male infertility is caused by a wide variety of undescribed
deficiencies; hence, there is a need to improve and establish robust sperm quality indica-
tors [36]. Over the years, several studies have identified a large number of sperm molecular
characteristics, such as receptors, ion channels, mRNA or proteins, that are involved in
sperm fertility and/or in embryo development [3–8,10–12,36]. Considering this, our next
aim was to investigate the association between PRR levels and basic sperm parameters,
human embryo development and reproductive success.
First, we evaluated the relationship between the PRR-positive cells with basic semen
parameters. Flow cytometry results showed that the presence of PRR has a negative effect
on sperm quality. Other membrane surface proteins are also negatively involved in sperm
motility such as membrane antigen CD52 [37], neprilysin (NEP) [38], µ-opioid receptor
(MOR) [39] or testicular isoform of angiotensin converting enzyme (tACE) [13]. Taking
into account that sperm motility appears to be essential for natural reproduction, currently,
the motility assay is the most reliable predictor of male factor infertility [12,37,40]. Based
on our results, PRR could negatively affect the sperm fertilizing capacity.
Additionally, the reproductive capacity of sperm is not only determined by its fer-
tilizing potential, but also implies the first stages of embryonic development. Successful
embryo development and subsequent pregnancy outcome are also linked to good quality
semen samples [9]. Owing to this reason, our next purpose was to investigate the relation-
ship between the percentage of sperm PRR with oocyte fertilization rates, embryo quality
parameters and the reproductive outcome during ART. To fulfill this objective, we analyzed
embryos from oocyte donation programs in order to avoid introducing bias concerning
oocyte quality, letting us study the sperm features without the wide heterogeneity of the
female factor [36]. Our study possesses some characteristics that reinforce the results
obtained: (1) sperm PRR was determined in the same sperm aliquot that was used for as-
sisted reproduction procedures, and (2) a large number of samples were included (n = 97).
Regarding the fertilization rates, despite a negative relationship noticed between PRR
and sperm motility, we did not observe any relationship between the PRR levels and
fertilization rates. However, this could be because all cycles included in this study were
inseminated by using intracitoplasmatic sperm injection (ICSI), in which the embryologist
has bypassed the previous steps that take place in the natural conception, such as reaching
the fertilization site and recognizing and fusing with the oocytes [9].
Since a sperm contribution may extend beyond fertilization, highlighting the fact that
early and late paternal effects may be determinants of normal embryo development [7],
we evaluated the relationship between PRR levels with embryo quality. Semen samples
with higher percentages of PRR-positive spermatozoa are associated with worse blasto-
cyst development. We found that blocked and degenerated blastocyst came from semen
samples with higher levels of sperm PRR. In the later in vitro phase of development, thus,
blastocysts with a higher implantation potential, such as expanded and hatching/hatched
blastocysts [41], are associated with lower percentages of PRR-positive spermatozoa. Re-
cent studies have reported that the PRR expressed during the embryo development plays
an important role during embryo development and cell survival or viability [34,42,43].
In this regard, our results suggest that not only the embryo expressed PRR but also the
spermatozoa expressed PRR can be involved in human embryo development.
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Previous studies report that PRR can play a key role in the invasion of trophectoderm
(TE) cells in the maternal uterus, which is essential for the embryo implantation process.
Nevertheless, we did not find any relation between the embryo transfer rate, clinical
pregnancy and live birth with PRR levels. However, we cannot deny a possible effect of
this receptor on the studied parameters because we only analyzed the first embryo transfer,
where only the high-quality embryos were transferred. In consequence, this positive
selection could be a factor of bias in our analysis, as have been described previously [36,44].
In brief, the present study describes for the first time the presence of PRR in human
spermatozoa at the gene and protein level, providing new findings about the existence
of the different axes of RAS in human sperm cells. The presence of different components
of RAS in human spermatozoa can provide evidence of a relevant role of this system
in sperm physiology. Specifically, higher levels of PRR in semen samples are associated
with low sperm quality, blocked and/or degenerated embryos, and defective blastocyst
development. Our results, thus, are consistent with the fact that low embryo quality and
poor blastocyst development are associated with deficiencies in mature spermatozoa [40].
In fact, the obtained results indicate that not only may failures at the chromatin or mRNA
level [26] compromise embryonic development, but sperm proteins can also be important
for correct embryo development, as has been previously reported [40].
Due to the ethical implications related to the generation and use of human embryos
in research, as well as the characteristics inherent to the microinjection technique itself,
the data shown do not allow us to ensure whether the injected spermatozoon is PRR
positive or negative. However, the results shown in this study reflect the association of the
PRR present in human spermatozoa, since surplus aliquots of samples used in assisted
reproduction treatments have been used for its analysis.
Our data reinforces the sperm role in embryo development, changing the old idea
of sperm as a mere “DNA vehicle carrier” [7,36]. These clinical observations led to the
hypothesis that PRR plays a negative role in sperm fertility, suggesting that PRR could
be considered as a potential marker of sperm quality. This negative association with
embryo health appears quite promising in predicting the quality of the embryo after
in vitro procedures. That is, why these data could serve as a first step to establish future
studies that show more directly and reliably the role of PRR of sperm for this purpose. All
these observations contribute to the hypothesis that sperm PRR could be used as a tool for
the negative selection of the most appropriate sperm for assisted reproduction techniques.
4. Materials and Methods
4.1. Ethical Approval
Semen samples were obtained from male partners of couples who underwent IVF
treatments with donated oocytes at the Clínica IVI Bilbao, Basque Country, Spain. Study
participation and sperm samples for research were obtained after written consent from
patients. In order not to intervene or harm any of the reproductive treatments evaluated
in this study, the aliquots of the sperm samples used in the molecular analyzes were
collected once the microinjection process was completed. All samples and data were kept
anonymous. All experiments were performed in accordance with relevant guidelines and
regulations.
4.2. Patients and Semen Analysis
A total of 120 patients were included between February 2014 and July 2015. A total of
23 normozoospermic samples were used to determine the presence and location of the PRR
in human spermatozoa and 97 semen samples were analyzed to elucidate the implication
of PRR in male fertility status and in embryo development.
Ejaculates were collected into sterile containers by masturbation on site, after a two-to-
five-day period of sexual abstinence, the day of oocyte retrieval and, after retrieval allowed
to liquefy at 37 ◦C and 5% (v/v) CO2 for 10 min before processing. Semen volume, as
well as sperm concentration and motility, were measured for each sample in duplicate,
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in a Mackler®Chamber (Sefi Laboratories, Haifa, Israel). According to World Health
Organization (WHO) guidelines [25], sperm motility was classified into three different
groups: (1) spermatozoa with progressive motility (PR), (2) non-progressive motility (NP),
and (3) non-motile spermatozoa (IM).
Subsequently, semen samples were centrifuged at 300 g for 20 min through a discon-
tinuous colloidal silica density gradient (45 to 90%) of PureSperm (Nidacon, Gothenberg,
Sweden). The pellets were then collected and washed (at 400 g for 5 min) in 2 mL of
culture medium Global®for fertilization Medium (Life Global Group, Brussels, Belgium)
and spermatozoa were re-suspended in 0.2 to 1 mL of medium for IVF techniques. After
this, the concentration and mobility of the obtained sperm samples were measured again.
Surplus spermatozoa remaining after being used for the ICSI technique were then
collected for molecular analysis by flow cytometry. The molecular data obtained were
related to basic sperm parameters (measured in fresh samples, as well as after being
processed), embryo quality parameters and reproductive outcomes.
4.3. Reverse Transcription-Polymerase Chain Reaction Analysis
The RNAs of spermatozoa and the human renal cell line (RC-124), used as a positive
control, were isolated with the Nucleo Spin RNA II kit (Macherey-Nagel, Düren, Germany),
including a DNase digestion step using an RNase-free DNase kit (QIAGEN, Limburgo,
Netherlands) to exclude possible contamination by genomic DNA. First-strand cDNA
synthesis was conducted using Superscript II RT (Invitrogen, LifeTechnology, Carlsbad,
CA, EEUU) according to the manufacturer’s instructions using 600 ng of RNA. Reverse
transcription-polymerase chain reaction (RT-PCR) was performed using SYBR®green mas-
ter mix (LifeTechnology, Carlsbad, CA, EEUU) with 2.5 µL of diluted cDNA and 0.25 µM
primers per 12.5 µL per reaction on an ABIPrism 7000 sequence detection system (Applied
Biosystems, LifeTechnology, Carlsbad, CA, EEUU). Specific oligonucleotide primer pairs
used for PCR were the following: human PRR: forward primer, 5-TGGTAGGGAAGGC
AAACTCA-3, and reverse primer, 5-TCAGAAAGAAAGAGCAGGTCAA-3; and human
ACTB (β-actin): forward primer, 5-GGCACCCAGCACAATGAAG-3, and reverse primer,
5-CCGATCCACACGGAGTACTTG-3, used as an internal control. These primers were
designed based on cDNA sequence. PCRs were performed using the following parameters:
25 ◦C for 10 min, 42 ◦C for 50 min followed by a final extension step at 70 ◦C for 15 min.
Analysis was carried out on samples measured in triplicates. The RT-PCR products were
also separated by 1.5% agarose gel electrophoresis. The amplicon sizes were verified by
comparison with a DNA size ladder.
4.4. Western Blotting
Isolated spermatozoa and human kidney samples were resuspended in modified
lysis buffer (radio-immunoprecipitation assay (RIPA) buffer (Sigma-Aldrich, Saint Luis,
MO, USA), protease and phosphatase inhibitor cocktail (Sigma-Aldrich, Saint Luis, MO,
USA) and DNase (Quiagen, Limburgo, Netherlands)) to obtain protein extracts. The
sperm samples were sonicated (two times 70% amplitude, 0.5 s 15 burst, and one time
40% amplitude, 0.5 s 15 burst), and incubated for 30 min on ice. Human kidney, used
as a positive control, was minced with sharp scissors, suspended in lysis buffer and
homogenized (Teflon glass), and then was incubated for 1 h on ice. The homogenates were
centrifuged at 18,800 g for 15 min at 4 ◦C, and the clear supernatants were then used for the
western blot studies. Protein concentrations were measured by Bicinchonicic acid method
(Sigma-Aldrich, San Luis, USA).
The protein extracts were diluted in Laemmli sample buffer containing β-mercaptoethanol
(5% v/v) and boiled for 5 min. Proteins (50 µg sperm protein; 30 µg kidney protein)
were loaded onto 10% resolving gels, separated by one-dimensional SDS-PAGE and then
transferred to polyvinylidene fluoride (PVDF) membranes (Amersham HybondTM, GE
Healthcare Bio-Sciences K. K. Tokyo, Japan) using the Mini Trans- Blot electrophoretic
transfer system (Bio-Rad Laboratories, Hercules, CA, USA). After transfer, each membrane
Int. J. Mol. Sci. 2021, 22, 3215 10 of 14
was blocked with Blotto (20 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1% Triton X-100) contain-
ing 5% nonfat dry milk (blocking buffer) for 1 h and then incubated with a dilution of
polyclonal rabbit anti-renin receptor antibody (Renin receptor antibody [H-85], sc-67390;
Santa Cruz Biotechnology, Inc., Heidelberg, Germany) at a dilution of 1:800 overnight at
4 ◦C. After washing (3 × 5 min) in Blotto buffer, the membrane was incubated for 1 h at
room temperature with peroxidase-conjugated goat anti-rabbit IgG antibody at a dilution
of 1:3000 (Goat anti-rabbit IgG HRP, ab6112; Abcam, Cambridge, UK). After washing
(3 × 5 min) with Blotto buffer, the peroxidase activity of the transfer proteins was revealed
by enhanced chemiluminescence (ECL).
4.5. Flow Cytometry
Spermatozoa were fixed with 4 % (v/v) paraformaldehyde (PAF) (Sigma-Aldrich, Saint
Louis, MO, USA). Samples were permeabilized with 0.5% Triton X-100 (10 min), incubated
in blocking medium (PBS with bovine fetal serum [BFS] (Biochrom, Cambridge, United
Kingdom) 10% (v/v)) for 30 min. The primary antibody designed to recognize human
PRR (renin receptor antibody [H-85], sc-67390; Santa Cruz Biotechnology, Inc., Heidelberg,
Germany) was diluted 1:250 in PBS with BFS 5% and incubated overnight at 4 ◦C. Goat
anti-rabbit IgG conjugated with Alexa Fluor 488 (Invitrogen, LifeTechnology, Carlsbad,
CA, EEUU) secondary antibody was used at a 1:2000 dilution and nuclei were stained
with 0.5 µg/mL Hoechst 33258 (Molecular Proves, Eugene, OR, USA). Primary antibody
specificity was performed using a negative unspecific rabbit immunoglobulin fraction
(normal) (Dako, Glostrup, Denmark) at the same concentration as the primary antibody,
as described elsewhere [45]. Secondary antibody specificity was performed omitting the
primary antibody before secondary antibody addition. The flow cytometry analysis was
performed on a GalliosTM flow cytometer (Becton Dickinson, San Jose, CA, USA). At least
10,000 events were analyzed per sample. Blue fluorescence (Hoechst 33258) and green
florescence (Alexa Fluor 488) were collected in the FL9 and FL1 sensors, respectively. To
exclude the debris from the analysis, we used a discrimination frame around the sperm
population on the forward (FSC) and side (SSC) scatter plots and only selected the Hoechst
33258-positive events. Results of the Alexa Fluor 488 and Hoechst 33258 fluorescence were
analyzed with the Summit v4.3 software.
4.6. Immunofluorescence
To localize the PRR in spermatozoa, isolated sperm cells were fixed with 4% PAF
and smeared onto a slide coated with poly-L-lysine. Triplicate slides were prepared for
each sample. Samples were permeabilized in the presence of 0.5% Triton X-100 (10 min)
and blocked in PBS and incubated for 30 min in PBS with FBS 10% (v/v). For indirect
immunofluorescence staining, slides were incubated with anti-PRR (renin receptor antibody
[H-85], sc-67390, Santa Cruz Biotechnology, Inc., Germany) at a dilution of 1:500 overnight
at 4 ◦C. This antibody recognized an extracellular domain of renin receptor of human
origin. Slides were then washed in PBS three times, incubated with Alexa Fluor 488 goat
anti-rabbit IgG secondary antibody (1:1000) (Molecular Probes, Eugene, OR, USA) for
1 h at room temperature in the absence of light and subsequently, washed in PBS three
times. We stained the nuclei with Hoechst 33258 at 2 min. Finally, the slides were mounted
using Fluoromount G reagent (Southern Biotech, Birmingham, AL USA), and examined
by confocal microscopy (Olympus Fluoview FV 500, Olympus. Tokio, Japan). Negative
controls were performed in the same way, except for the omission of the primary antibody
before secondary antibody addition.
4.7. Assisted Reproductive Technology Procedures
The employment of an oocyte donation model reduces the variability of oocyte quality
associated with female infertility and reduces endometrial receptivity variability associated
with ovarian stimulation protocols. Therefore, it allowed us to analyze the relationship be-
tween PRR-positive spermatozoa and fertilization rates, embryo quality and development,
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implantation rates, and reproductive outcomes controlling the potential bias caused by
female factor [36]. Recruitment and management protocols for oocyte donors, as well as
the steroid replacement on the recipients have been previously described [46]. Recovered
mature oocytes (metaphase II) were inseminated by means of ICSI after the protocol that
was described elsewhere [47]. Subsequently, microinjected oocytes were cultured in a
normal Petri dishes (Falcon, Welwyn, UK) in 20 mL drops of culture media (Cleavage
Medium; Cook Medical IVF, Limerick, Ireland) under mineral oil. After fertilization check-
ing, zygotes were placed individually in a new pre-equilibrated Petri dish with drops of
50 mL of the same culture medium covered with 7 mL of mineral oil. On the basis of
previous medical criteria, all patients were assigned a day of embryo transference (day 3
vs. day 5 or 6); depending on that clinical decision, embryos were cultured until embryo
transfer at day 3 in Cleavage Medium (Cook Medical IVF), and from day 3 to day 5 in
CCM Medium (Vitrolife, Göteborg, Sweden). Both, microinjected oocytes and embryos
were cultured at 37 ◦C in a controlled atmosphere of CO2 at 5% (v/v) in a conventional
incubator (Heraeus; Heracell, Hanau, Alemania).
4.8. Fertilization Rates, Embryo Quality, Transference, Biochemical and Clinical Pregnancy and
Live-Birth Outcome
Successful fertilization was verified by confirmation of two polar bodies and two
pronuclei 16 to 19 h after microinjection. Embryo quality was assessed at both the cleavage
stage (days 2 and 3) or early embryos, and in the later phase of in vitro development
(days 5 and 6), at the blastocyst stage. In both cases, the morphology of the embryos
was evaluated at 40× magnification under an inverted microscope. Early embryos were
categorized in four grades from A (high quality) to D (low quality) considering the number
of blastomeres, their fragmentation, multinucleation and symmetry, the presence and
number of vacuoles, and the appearance of the zona pellucida, according to the Spanish
Association of Reproduction Biology Studies (ASEBIR) criteria, when grade A gave the
best and grade D the worst prognosis for implantation for a combination of the various
aforementioned morphologic parameters [48]. At day 2 (44 to 47 h postinsemination), grade
A embryos have four cells, <11% fragmentation, even size and no multinucleation; grade
B embryos have two or five cells with 11 to 25% fragmentation and no multinucleation;
grade C embryos have two to six cells, 26 to 35% fragmentation, uneven cell allowed
but no multinucleation; and grade D, if the embryo has one or greater than six cells,
multinucleation, abundant vacuoles and >35% fragmentation or type IV fragmentation [48].
To classify the day 3 embryos (67 to 71 h postinsemination), all four categories were
assigned according to the evolution of the embryos from day 2 to day 3 [49]. Grade A
embryos have seven to eight cells, <10% fragmentation, even size and no multinucleation;
grade B embryos have seven to eight cells with 11 to 25% fragmentation, nine evenly
sized cells or more and no multinucleation; grade C embryos have less than six cells, 26
to 35% fragmentation, uneven cells allowed but no multinucleation; and grade D, if the
embryo has six cells or less and observation of multinucleation, >35% fragmentation or
type IV fragmentation [48]. All embryos were included in the determination of the patient’s
mean embryo score. Embryo quality was related to sperm PRR in two different ways:
as an individual concept by grouping the embryos according to quality or determining
an embryo quality score per cohort. To assess the embryo quality score per cohort, each
embryo grade was assigned a value (1, 2, 3, 4); grade A embryos were assigned a value of 1
and grade D a value of 4. Moreover, some of the early embryo parameters were calculated
as an average of the embryo cohort per patient, including the fertilization rate, embryo
fragmentation, average number of cells and symmetry.
Human blastocysts were scored on day five and six of embryo development (114 to
118 and 136 to 140 h post-insemination, respectively). Blastocysts were grouped in four
groups according to the expansion of the blastocoele cavity: early (BT), expanding (BC),
expanded (BE), or hatching or hatched (BHi) blastocysts [49]. In addition, embryos with
slower development that remained at the compact morula stage (MC), as well as embryos
that were blocked or degenerated (BD) were also considered. To investigate the relationship
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between sperm PRR and blastocyst viability, blastocysts were classified as viable (V) if they
were transferred or frozen, or non-viable (NV), if they were arrested or of poor quality.
In each case, transfers were performed on day 3 or day 5 to 6 after microinjection,
and only one or two good embryos were selected for transfer. Supernumerary embryos
were frozen for eventual future transfers. Biochemical pregnancy was considered after the
detection of a positive result in the β-hCG test (defined as having a serum level of β-hCG
greater than 10 IU/mL) in the recipients 16 days after the donor’s oocyte retrieval. Clinical
pregnancy was determined by observing a gestational sac with a fetal heartbeat at seven
weeks of pregnancy detected by transvaginal ultrasound, and live-birth outcome when
the cycle ended with an infant born alive. In estimating reproductive success, we only
considered the first embryo transfer.
4.9. Statistical Analysis
The percentages of PRR-positive sperm cells were associated with basic sperm pa-
rameters, embryo quality parameters and reproductive success. The normality of the
data was evaluated using the Kolmogorov–Smirnov test. Normal data distributions were
not detected, so non-parametric tests were used. To analyze the correlation between the
number of positive sperm cells for PRR and basic sperm parameters and embryo quality
parameters, we used a scatter plot and Spearman´s rank correlation analyses. Differences
between PRR-positive sperm cells and fertilization rates, late embryo development, blas-
tocysts viability, embryo implantation, pregnancy outcomes and live-birth success were
analyzed by Kruskal–Wallis and Mann–Whitney U tests. Statistical significance and high
statistical significance were determined by p values (p < 0.05 and p < 0.01, correspondingly).
Statistical analyses were performed using the IBM SPSS Statistics 22 software.
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